Psilera is a biopharmaceutical company revolutionizing the development of novel serotonergic drugs which provide rapid therapeutic benefit and fewer side effects than conventional treatments. Their world-class scientific and executive team reimagine psychoactive natural products into effective and insurance-backed take-home therapies for psychiatric, addiction, and neurodegenerative disorders. Their proprietary drug discovery engine, Psilera Third Eye, combines novel syntheses of new compounds with an AI-enabled screening platform to design next-generation neurological drugs at the atomic level. By designing next-generation psychedelics without hallucinogenic effects, these drugs have take-home potential with increased patient access. Psilera’s novel drugs aim to be first and best-in-class for a variety of neurological disorders.